Skip to main content
Erschienen in: Journal of Gastrointestinal Cancer 4/2011

01.12.2011 | Brief Communication

Pancreatic Resection for Metastatic Melanoma. Case Report and Review of the Literature

verfasst von: Cosimo Sperti, Maria Laura Polizzi, Valentina Beltrame, Margherita Moro, Sergio Pedrazzoli

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Pancreatic metastasis from several malignancies are increasingly encountered in clinical practice, and the usefulness of surgical resection has been suggested for certain neoplasms. Isolated pancreatic metastasis from malignant melanoma is a rare occurrence, and the role of surgery as an adjunct to systemic therapy for melanoma metastatic to a solitary or multiple sites is still debated.

Case Report

We report a patient with melanoma of unknown primary site metastatic simultaneously to the lung and pancreas 3 years after axillary lymph node dissection. Distal pancreatectomy with splenectomy and video thoracoscopic assisted resection of pulmonary metastasis were performed. The postoperative course was uneventful, but 6 months after surgery, the patient experienced single pulmonary recurrence. During chemotherapy with different drugs, pulmonary lesion remained stable for 1 year, and no abdominal recurrence occurred. After then, the size of the lesion progressively increased and a second metastasis occurred in the lung. Five months later, brain metastases occurred, and the patients died 24 months after surgery. Sixteen pancreatic resections for metastatic malignant melanoma, reported with adequate clinical details, were also retrieved from the literature.

Conclusion

In spite of the very limited experience, it appears that surgical resection is only a palliative procedure, because long-term survival is a rare event. However, considering the lack of effective systemic therapy, surgery may be considered as a part of an aggressive multidisciplinary approach in selected cases with malignant melanoma metastatic to single or multiple visceral sites.
Literatur
2.
Zurück zum Zitat McLoughlin JM, Zager JS, Sondak VK, Berk LB. Treatment options for limited or symptomatic metastatic melanoma. Cancer Control. 2008;15:239–47.PubMed McLoughlin JM, Zager JS, Sondak VK, Berk LB. Treatment options for limited or symptomatic metastatic melanoma. Cancer Control. 2008;15:239–47.PubMed
4.
8.
Zurück zum Zitat Sobin LH, Wittekind C. AJCC: TNM classification of malignant tumors. 6th ed. New York: John Wiley and Sons, Inc.; 2002. Sobin LH, Wittekind C. AJCC: TNM classification of malignant tumors. 6th ed. New York: John Wiley and Sons, Inc.; 2002.
10.
Zurück zum Zitat Masetti M, Zanini N, Martuzzi F, Fabbri C, Mastrangelo L, Landolfo G, et al. Analysis of prognostic factors in metastatic tumors of the pancreas. A single-center experience and review of the literature. Pancreas. 2010;39:135–43. doi:10.1097/MPA.0b013e3181bae9b3.PubMedCrossRef Masetti M, Zanini N, Martuzzi F, Fabbri C, Mastrangelo L, Landolfo G, et al. Analysis of prognostic factors in metastatic tumors of the pancreas. A single-center experience and review of the literature. Pancreas. 2010;39:135–43. doi:10.​1097/​MPA.​0b013e3181bae9b3​.PubMedCrossRef
11.
Zurück zum Zitat Wong JH, Euhus DM, Morton DL. Surgical resection for metastatic melanoma to the lung. Arch Surg. 1988;123:1091–5.PubMed Wong JH, Euhus DM, Morton DL. Surgical resection for metastatic melanoma to the lung. Arch Surg. 1988;123:1091–5.PubMed
12.
Zurück zum Zitat Tafra L, Dale PS, Wanek LA, Romming KP, Morton DL. Resection and adjuvant immunotheraphy for melanoma metastatic to the lung and thorax. J Thorac Cardiovasc. 1991;110:119–28. doi:10.1016/S0022-5223(05)80017-0. discussion 129.CrossRef Tafra L, Dale PS, Wanek LA, Romming KP, Morton DL. Resection and adjuvant immunotheraphy for melanoma metastatic to the lung and thorax. J Thorac Cardiovasc. 1991;110:119–28. doi:10.​1016/​S0022-5223(05)80017-0. discussion 129.CrossRef
15.
Zurück zum Zitat Roland CF, Van Heerden JA. Nonpancreatic primary tumors with metastasis to the pancreas. Surg Gynecol Obstet. 1989;168:345–7.PubMed Roland CF, Van Heerden JA. Nonpancreatic primary tumors with metastasis to the pancreas. Surg Gynecol Obstet. 1989;168:345–7.PubMed
16.
Zurück zum Zitat Pingpank JF, Hoffman JP, Sigurdson ER, Ross E, Sasson AR, Eisenberg BL. Pancreatic resection for locally advanced primary and metastatic nonpancreatic neoplasms. Am Surg. 2002;68:337–41.PubMed Pingpank JF, Hoffman JP, Sigurdson ER, Ross E, Sasson AR, Eisenberg BL. Pancreatic resection for locally advanced primary and metastatic nonpancreatic neoplasms. Am Surg. 2002;68:337–41.PubMed
17.
Zurück zum Zitat Lasser Ph, Hardy Ch, Cheynel C, Bognel C. Pancreaticoduodenectomy for pancreatic metastasis from malignant melanoma. J Chir. 1990;127:494–5. Lasser Ph, Hardy Ch, Cheynel C, Bognel C. Pancreaticoduodenectomy for pancreatic metastasis from malignant melanoma. J Chir. 1990;127:494–5.
21.
Zurück zum Zitat Nikfarjam M, Evans P, Christophi C. Pancreatic resection for metastatic melanoma. HPB. 2003;5:174–9.PubMedCrossRef Nikfarjam M, Evans P, Christophi C. Pancreatic resection for metastatic melanoma. HPB. 2003;5:174–9.PubMedCrossRef
22.
Zurück zum Zitat Carboni F, Graziano F, Lonardo MT, Lepiane P, Santoro R, Lorusso R, et al. Pancreaticoduodenectomy for pancreatic metastatic melanoma. J Exp Clin Cancer Res. 2004;23:539–43.PubMed Carboni F, Graziano F, Lonardo MT, Lepiane P, Santoro R, Lorusso R, et al. Pancreaticoduodenectomy for pancreatic metastatic melanoma. J Exp Clin Cancer Res. 2004;23:539–43.PubMed
23.
Zurück zum Zitat Crippa S, Angelini C, Mussi C, Bonardi C, Romano F, Sartori P, et al. Surgical treatment of metastatic tumors to the pancreas: a single center experience and review of the literature. World J Surg. 2006;30:1536–42. doi:10.1007/s00268-005-0464-4.PubMedCrossRef Crippa S, Angelini C, Mussi C, Bonardi C, Romano F, Sartori P, et al. Surgical treatment of metastatic tumors to the pancreas: a single center experience and review of the literature. World J Surg. 2006;30:1536–42. doi:10.​1007/​s00268-005-0464-4.PubMedCrossRef
24.
Zurück zum Zitat Belagyi T, Zsoldos P, Makay R, Issekutz A, Olah A. Multiorgan resection (including the pancreas) for metastatis of cutaneous malignant melanoma. JOP J Pancreas online. 2006;7:234–40. Belagyi T, Zsoldos P, Makay R, Issekutz A, Olah A. Multiorgan resection (including the pancreas) for metastatis of cutaneous malignant melanoma. JOP J Pancreas online. 2006;7:234–40.
26.
Zurück zum Zitat Vagefi PA, Stangenberg L, Krings G, Forcione DG, Wargo JA (2009). Ocular melanoma metastatic to the pancreas after 28-year disease-free interval. Surgery (Epub ahead of print). Vagefi PA, Stangenberg L, Krings G, Forcione DG, Wargo JA (2009). Ocular melanoma metastatic to the pancreas after 28-year disease-free interval. Surgery (Epub ahead of print).
28.
Zurück zum Zitat Guillot B, Khamari A, Cupissol D, Delanunay M, Bedane C, Dreno B, et al. Temozolomide associated with PEG- interferon in patients with metastatic melanoma: a multicenter prospective phase I/II study. Melanoma Res. 2008;18:141–6. doi:10.1097/CMR.0b013e3282f6309c.PubMedCrossRef Guillot B, Khamari A, Cupissol D, Delanunay M, Bedane C, Dreno B, et al. Temozolomide associated with PEG- interferon in patients with metastatic melanoma: a multicenter prospective phase I/II study. Melanoma Res. 2008;18:141–6. doi:10.​1097/​CMR.​0b013e3282f6309c​.PubMedCrossRef
29.
Zurück zum Zitat O’Day S, Gonzalez R, Lawson D, Weber R, Hutchins L, Anderson C, et al. Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma. J Clin Oncol. 2009;27:5452–8. doi:10.1200/JCO.2008.17.1579.PubMedCrossRef O’Day S, Gonzalez R, Lawson D, Weber R, Hutchins L, Anderson C, et al. Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma. J Clin Oncol. 2009;27:5452–8. doi:10.​1200/​JCO.​2008.​17.​1579.PubMedCrossRef
Metadaten
Titel
Pancreatic Resection for Metastatic Melanoma. Case Report and Review of the Literature
verfasst von
Cosimo Sperti
Maria Laura Polizzi
Valentina Beltrame
Margherita Moro
Sergio Pedrazzoli
Publikationsdatum
01.12.2011
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 4/2011
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-010-9169-5

Weitere Artikel der Ausgabe 4/2011

Journal of Gastrointestinal Cancer 4/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.